nRBC is being developed to treat traumatic brain injury complicated with hypotension as an orphan indication.



Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in both civilian and military settings.  Secondary insults, such as hemorrhagic shock (HS), are common and have a devastating impact on outcome. 

nRBC is specifically designed to meet un-met critical care needs where there is inadequate blood flow and  insufficient oxygen delivery.  In cases of TBI+HS, nRBC can stabilize hemodynamics to increase oxygen delivery to the brain without increasing intracranial pressure (ICP) and brain edema while protecting the brain cells from other secondary damage.